mercredi 2 mai 2018

Onco Actu du 2 mai 2018

1. Biologie

Cryo-EM Images Capture Key Enzyme Tied to Cancer, Aging [NIH Director's Blog]

3.1.1 Prévention - Tabac - e-cigs

FDA, FTC take action against companies misleading kids with e-liquids that resemble children’s juice boxes, candies and cookies [FDA]

Liquid nicotine for e-cigs looks like kids’ juice boxes and candy, government says [Washington Post]

3.3 Prévention - Vaccins

Doctors paying for sons to have cancer jab [BBC News]

4. Dépistage, diagnostic et pronostic

Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival [NCI]

4.2 Dép., diag. & prono. - Génome

Cracking the Code of Life—at Light Speed [Wall Street Journal]

4.9 Dép., diag. & prono. - Sein

New approach for hard-to-treat BRCA breast cancer shrinks tumours twice as fast [The Telegraph]

Gene test might benefit women with hard-to-treat breast cancer [Cancer Research UK]

5. Traitements

Poziotinib as a Clinically Active Inhibitor of EGFR and HER2 exon 20 mutations [ESMO]

5.10 Traitements - Essais

Unreported clinical trial of the week: Temsirolimus and Bevacizumab for cancer patients (NCT01010126) [BMJ]

5.12.1 Immunothérapies - partenariats

George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome [Forbes]

Harvard's Wyss Institute partners with Cellectis to recode the human genome [PR Newswire]

5.12.2 Immunothérapies - CAR-T

SUPRA CAR T cell system provides more of cosmetic rather than a real advance [NIHilist's Immunology]

5.12.3 Immunothérapies-combinaisons

Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination [FierceBiotech]

IDO Appears to Have Wiped Out [In the Pipeline]

Bristol-Myers Latest to Drop IDO Studies in Wake of Incyte Failure [Xconomy]

IDO rout: Pivotal trials with Bristol-Myers, Merck and AstraZeneca dumped in wake of Incyte’s PhIII implosion [EndPoints]

5.12.5 Immunothérapies - Pharma

Leena Gandhi steps out of Keytruda spotlight and into a top research job at I/O laggard Eli Lilly [EndPoints]

5.12.6 Immunothérapies - AMM

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma [Novartis]

U.S. approves Novartis cell therapy for lymphoma [Reuters]

Kymriah wins second FDA OK, boosting hope for Novartis’ low CAR-T sales [EndPoints]

5.12.8 Immunothérapies - Economie

Merck’s Dangerous Keytruda Success [Bloomberg]

5.2 Pharma

Karyopharm to pursue FDA approval for multiple myeloma drug based on new study results [STAT]

Karyopharm stock soars on selinexor’s positive PhIIb update, plans for an NDA [EndPoints]

5.2.3 Pharma - économie

Pfizer first-quarter results miss estimates as key drug sales fall short [Reuters]

5.3.4 Traitements - AMM (FDA, EMA,...)

Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer [AstraZeneca]

Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma [Novartis]

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label [Amgen]

CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence [Roche]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018 [EMA]

EMA Recommends Extension of Indications for Pertuzumab [ESMO]

EMA Recommends Extension of Indications for Osimertinib [ESMO]

FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations [FDA]

5.4 Traitements - Economie

China to cut import value-added tax on cancer drugs from May 1 [Reuters]

Value-Based Pricing for Drugs [JAMA]

5.9.1 AACR - sein

PARP Drugs Help Some Breast Cancer Patients, But They're No Magic Bullet [Forbes]

5.9.4 AACR - poumon

Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer [NCI]

6. Lutte contre les cancers

NIH opens nationwide enrollment for huge precision medicine initiative [STAT]

6.1 Observation

Ovarian cancer diagnoses 'will rise 55% in the next 20 years' [The Guardian]

A rare eye cancer showed up in three friends. Doctors want to know if the cases are connected. [Washington Post]

6.3 Associations/Fondations

A better understanding of brain tumour biology will bring new treatments [Cancer Research UK]

Cancer Research UK appoints new chief executive [Cancer Research UK]

Brain tumour research to get £18m injection [The Guardian]

6.4 Médico-éco

For Cancer Centers, Proton Therapy’s Promise Is Undercut by Lagging Demand [NY Times]

6.5 Médecines alternatives

How is it that in 2018 cancer Stanislaw Burzynski is still preying on desperate cancer patients? [Respectful Insolence]

6.7.1 IA/bioinformatique

Out to ‘rethink the drug design process,’ AI star Daphne Koller is creating a new machine learning venture at insitro with some heavyweight backers [EndPoints]

6.7.2 Applis

App turns smartphones into data crunchers to help find cancer treatment [The Telegraph]

Cancer researchers need phones to process data [BBC News]

6.8 Communication

Peter Tunney: How the largest art movement in history can help reduce cancer disparities [The Cancer Letter]

Miami’s Sylvester uses cool art to bridge disparities—and meet NCI’s new requirement [The Cancer Letter]